Literature DB >> 8370162

A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.

D Chargelegue1, C M O'Toole, B T Colvin.   

Abstract

The IgG response to HIV-1 p17 gag protein was studied for up to 6 years in 12 HIV-1-infected patients with haemophilia, who had seroconverted between 1982 and 1985. To assess any prognostic value, p17 IgG titres were compared with p24 IgG titres, CD4 cell counts and p24 antigenaemia. p17 IgG avidity index was also examined. A strong similarity was found between the IgG titre to HIV-1 p17 and that to p24. In patients who developed AIDS the decline in p17 IgG titres could precede by several years the drop in CD4 cells to under 200 cells/microliters; whereas some long-term asymptomatic patients (CDCII) had increasing p17 IgG titres and stable CD4 cell counts. Declining p17 and p24 IgG titres were not always associated with an increase in p24 antigenaemia. IgG titres were found to be better predictors of disease progression than CD4 cell counts or p24 antigenaemia. Patients who developed AIDS during the study were also characterized by a lower p17 IgG avidity than patients who remained asymptomatic. This result suggests that IgG avidity could have prognostic relevance and be of importance for host resistance to AIDS onset.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370162      PMCID: PMC1554909          DOI: 10.1111/j.1365-2249.1993.tb08181.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study.

Authors:  C M O'Toole; M W Lowdell; D Chargelegue; B T Colvin
Journal:  AIDS Res Hum Retroviruses       Date:  1992-08       Impact factor: 2.205

Review 2.  Cellular interactions in the humoral immune response.

Authors:  E S Vitetta; R Fernandez-Botran; C D Myers; V M Sanders
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

3.  Serum cholesterol and the risk of colorectal cancer.

Authors:  E J Holtzman; S Yaari; U Goldbourt
Journal:  N Engl J Med       Date:  1987-07-09       Impact factor: 91.245

4.  Acid hydrolysis of serum samples to increase detection of HIV antigen.

Authors:  T Mathiesen; V A Sundqvist; J Albert; E Ohlsson; B Wahren
Journal:  J Virol Methods       Date:  1988-12       Impact factor: 2.014

5.  Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs.

Authors:  M J Chou; T H Lee; A Hatzakis; T Mandalaki; M F McLane; M Essex
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

6.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

7.  Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.

Authors:  F Barin; M F McLane; J S Allan; T H Lee; J E Groopman; M Essex
Journal:  Science       Date:  1985-05-31       Impact factor: 47.728

8.  Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.

Authors:  P A Broliden; L Morfeldt-Månsson; J Rosen; M Jondal; B Wahren
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

9.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline.

Authors:  J M Lange; F de Wolf; W J Krone; S A Danner; R A Coutinho; J Goudsmit
Journal:  AIDS       Date:  1987-09       Impact factor: 4.177

View more
  6 in total

1.  Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Authors:  K S Cole; J L Rowles; B A Jagerski; M Murphey-Corb; T Unangst; J E Clements; J Robinson; M S Wyand; R C Desrosiers; R C Montelaro
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

2.  Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections.

Authors:  K S Cole; M Murphey-Corb; O Narayan; S V Joag; G M Shaw; R C Montelaro
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002.

Authors:  Carmem A de Freitas Oliveira; Mirthes Ueda; Rosemeire Yamashiro; Rosângela Rodrigues; Haynes W Sheppard; Luís Fernando de Macedo Brígido
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

4.  The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.

Authors:  D Chargelegue; C M Stanley; C M O'Toole; B T Colvin; M W Steward
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

Review 5.  Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.

Authors:  Martyn A French; Laila N Abudulai; Sonia Fernandez
Journal:  Vaccines (Basel)       Date:  2013-08-09

6.  Decreasing Proportion of Recent Infections among Newly Diagnosed HIV-1 Cases in Switzerland, 2008 to 2013 Based on Line-Immunoassay-Based Algorithms.

Authors:  Jörg Schüpbach; Christoph Niederhauser; Sabine Yerly; Stephan Regenass; Meri Gorgievski; Vincent Aubert; Diana Ciardo; Thomas Klimkait; Günter Dollenmaier; Corinne Andreutti; Gladys Martinetti; Marcel Brandenberger; Martin D Gebhardt
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.